UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

The New England journal of medicine, 2007-10, Vol.357 (15), p.1496-1506

2007

Volltextzugriff (PDF)

Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience

Journal of clinical oncology, 2007-08, Vol.25 (24), p.3699-3704

2007

Volltextzugriff (PDF)

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

Journal of clinical oncology, 2003-03, Vol.21 (6), p.976-983

2003

Volltextzugriff (PDF)

Pharmacodynamic Markers of Perifosine Efficacy

Clinical cancer research, 2007-12, Vol.13 (24), p.7421-7431

2007

Volltextzugriff (PDF)

Bisphosphonates: game changers?

Oncology (Williston Park, N.Y.), 2015-01, Vol.29 (1), p.16, 42-42

Craig Henderson, I

2015

Volltextzugriff (PDF)

Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer

Journal of clinical oncology, 2004-10, Vol.22 (19), p.3893-3901

2004

Volltextzugriff (PDF)

Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342

Journal of clinical oncology, 2004-06, Vol.22 (11), p.2061-2068

2004

Volltextzugriff (PDF)

Sequencing of Chemotherapy and Radiation Therapy in Early-Stage Breast Cancer: Updated Results of a Prospective Randomized Trial

Journal of clinical oncology, 2005-03, Vol.23 (9), p.1934-1940

2005

Volltextzugriff (PDF)

Targeted therapy: a sea change in the treatment of cancer

Oncology (Williston Park, N.Y.), 2012-11, Vol.26 (11), p.1035, 1039-1039

Henderson, I Craig

2012

Volltextzugriff (PDF)

p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)

Clinical cancer research, 2011-08, Vol.17 (15), p.5170-5178

2011

Volltextzugriff (PDF)

Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients

Journal of clinical oncology, 2005-07, Vol.23 (19), p.4287-4297

2005

Volltextzugriff (PDF)

Effect of Addition of Adjuvant Paclitaxel on Radiotherapy Delivery and Locoregional Control of Node-Positive Breast Cancer: Cancer and Leukemia Group B 9344

Journal of clinical oncology, 2005-01, Vol.23 (1), p.30-40

2005

Volltextzugriff (PDF)

With Decades of Perspective, Craig Henderson Observes That Treatment of Breast Cancer Has Come a Long Way

Oncology (Williston Park, N.Y.), 2017-05, Vol.31 (5), p.346-348

Henderson, I Craig

2017

Volltextzugriff (PDF)

The Sequencing of Chemotherapy and Radiation Therapy after Conservative Surgery for Early-Stage Breast Cancer

The New England journal of medicine, 1996-05, Vol.334 (21), p.1356-1361

1996

Volltextzugriff (PDF)

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

JAMA : the journal of the American Medical Association, 2006-04, Vol.295 (14), p.1658

2006

Volltextzugriff (PDF)

Impact of High-Dose Chemotherapy on the Ability to Deliver Subsequent Local–Regional Radiotherapy for Breast Cancer: Analysis of Cancer and Leukemia Group B Protocol 9082

International journal of radiation oncology, biology, physics, 2010-04, Vol.76 (5), p.1305-1313

2010

Volltextzugriff (PDF)

Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer

The New England journal of medicine, 2004-09, Vol.351 (10), p.971-977

2004

Volltextzugriff (PDF)

Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy

Expert review of anticancer therapy, 2007-07, Vol.7 (7), p.919-943

2007

Volltextzugriff (PDF)

The relationship between prognostic and predictive factors in the management of breast cancer

Breast cancer research and treatment, 1998-01, Vol.52 (1-3), p.261-288

1998

Volltextzugriff (PDF)

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer

JAMA : the journal of the American Medical Association, 2005-03, Vol.293 (9), p.1073

2005

Volltextzugriff (PDF)

Natural History of More Than 20 Years of Node-Positive Primary Breast Carcinoma Treated With Cyclophosphamide, Methotrexate, and Fluorouracil–Based Adjuvant Chemotherapy: A Study by the Cancer and Leukemia Group B

Journal of clinical oncology, 2003-05, Vol.21 (9), p.1825-1835

2003

Volltextzugriff (PDF)

Can we abandon anthracyclines for early breast cancer patients?

Oncology (Williston Park, N.Y.), 2011-02, Vol.25 (2), p.115-127

Henderson, I Craig

2011

Volltextzugriff (PDF)

Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B

Journal of clinical oncology, 2008-05, Vol.26 (14), p.2364-2372

2008

Volltextzugriff (PDF)

1 – 25 von 1.070

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(802)
Mit Volltextzugriff
(853)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

Pharmacodynamic Markers of Perifosine Efficacy

Bisphosphonates: game changers?

Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer

Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342

Sequencing of Chemotherapy and Radiation Therapy in Early-Stage Breast Cancer: Updated Results of a Prospective Randomized Trial

Targeted therapy: a sea change in the treatment of cancer

p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)

Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients

Effect of Addition of Adjuvant Paclitaxel on Radiotherapy Delivery and Locoregional Control of Node-Positive Breast Cancer: Cancer and Leukemia Group B 9344

With Decades of Perspective, Craig Henderson Observes That Treatment of Breast Cancer Has Come a Long Way

The Sequencing of Chemotherapy and Radiation Therapy after Conservative Surgery for Early-Stage Breast Cancer

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

Impact of High-Dose Chemotherapy on the Ability to Deliver Subsequent Local–Regional Radiotherapy for Breast Cancer: Analysis of Cancer and Leukemia Group B Protocol 9082

Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer

Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy

The relationship between prognostic and predictive factors in the management of breast cancer

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer

Natural History of More Than 20 Years of Node-Positive Primary Breast Carcinoma Treated With Cyclophosphamide, Methotrexate, and Fluorouracil–Based Adjuvant Chemotherapy: A Study by the Cancer and Leukemia Group B

Can we abandon anthracyclines for early breast cancer patients?

Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel

Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B

Suchergebnisse filtern